

Product Information

3-Amino-9-ethylcarbazole

Tablets


A6926

Product Description

CAS Number: 132-32-1

Synonyms: AEC, 9-ethylcarbazol-3-amine

Molecular Weight: 210.27

Molecular Formula: C₁₄H₁₄N₂

3-Amino-9-ethylcarbazole (AEC) is a chromogen that is suitable for use in immunoblotting and immunohistochemical staining procedures which utilize horseradish peroxidase (HRP) conjugates. The reaction of AEC with HRP produces an insoluble end product that is red in color and can be observed visually, in 0.05 M acetate buffer at pH 5.^{1,2} An aqueous mounting medium should be used with this product, as the end product is alcohol-soluble.

Each A6926 tablet contains 20 mg of AEC substrate. Several theses³ and dissertations⁴⁻¹⁶ have cited use of product A6926 in their protocols.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

This product may be stored at room temperature.

Solubility

This product is tested for solubility whereby one tablet is dissolved in 5 mL of DMF (*N,N*-dimethylformamide).

Usage

For use as an HRP substrate

- Dissolve 1 tablet in 2.5 mL of DMF.
- Add 2.5 mL of the AEC/DMF solution to 47.5 mL of 50 mM acetate buffer (pH 5.0), with stirring.
- Add 25 µL of fresh 30% (w/w) hydrogen peroxide immediately prior to use.
- If necessary, filter through a 0.2 µm filter.

References

1. Graham, R.C. Jr., *et al.*, *J. Histochem. Cytochem.*, **13(2)**, 150-152 (1965).
2. Kaplow, L.S., *Am. J. Clin. Path.*, **63(3)**, 451 (1975).
3. Trondsen, Monica, "Preparing for an influenza pandemic: Re-evaluating the use of the whole inactivated virus vaccine formulation". University of Bergen, M.Sc. thesis, p. 18 (2009).
4. Dollery, Clare Margaret, "Matrix Metalloproteinase Inhibitors in Angioplasty Restenosis: Pharmacological and Gene Transfer Approaches". University College London, Ph.D. dissertation, p. 84 (1998).
5. Sill, Björn, "Wirkung von Sauerstoffradikalen auf die Endothelin-1-Synthese in humanen Arteria mammaria interna-Gefäßen *ex vivo*" ("Effect of oxygen radicals on endothelin-1 synthesis in human internal mammary artery vessels *ex vivo*"). Universität Hamburg, Dr. med. dissertation, p. 31 (2005).

6. Chui, Jeanie Jin Yee, "The role of substance P in the pathogenesis of pterygia". University of New South Wales, Ph.D. dissertation, pp. 66, 120 (2007).
7. Biot, Claire, "BCG-therapie et cancer de la vessie: la caracterisation et la modelisation de la reponse immune au BCG dans la vessie revelent des strategies pour l'amelioration de la reponse anti-tumorale" ("BCG immunotherapy for bladder cancer: characterization and modeling of the bladder immune response to BCG identify strategies for improving anti-tumor activity"). Université Pierre et Marie Curie, Ph.D. dissertation, pp. 229, 230 (2012).
8. Guimond, David, "Treatment of experimental asthma using a novel peptide inhibitor of the inducible T cell kinase". University of California San Diego, Ph.D. dissertation, pp. 91, 205 (2012).
9. Stemke, Anastasia, "Immunotherapy with tumor antigen-specific T cells in *ret* transgenic mouse melanoma model". Ruperto-Carola Universität Heidelberg, Dr. rer. nat. dissertation, pp. 26, 27 (2013).
10. Koziol, Uriel, "Molekulare und entwicklungsbiologische Charakterisierung des *Echinococcus multilocularis* Stammzellsystems" ("Molecular and developmental characterization of the *Echinococcus multilocularis* stem cell system"). Julius-Maximilians Universität Würzburg, Dr. rer. nat. dissertation, p. 313 (2013).
11. Shrestha, Anjana, "Semaphorin 3A and Class 4 Semaphorins in Tooth Innervation and Development". University of Bergen, Ph.D. dissertation, pp. 45, 46 (2014).
12. Bergmann, Tobias, "Determination of quantitative peptide-binding motifs of four common equine MHC class I alleles, and identification of an equine herpesvirus type 1-derived cytotoxic T lymphocyte epitope". Freien Universität Berlin, Dr. rer. nat. dissertation, pp. 28, 48 (2016).
13. Sordé, Laetitia, "Anti-inflammatory effects of intravenous immunoglobulin (IVIg): what are the mechanisms of action?". Universität Basel, Ph.D. dissertation, p. 56 (2016).
14. Idrees, Muneeb Ahmad, "Role of complement receptors in the induction of retroviral-specific CTL responses by dendritic cells". Medical University of Innsbruck, Ph.D. dissertation, pp. 38, 39 (2017).
15. Hamm, Michael, "The role of the transcription factor BRN2 in melanomagenesis". Université Paris Sciences et Lettres, Ph.D. dissertation, p. 82 (2018).
16. Penner, Inessa, "The impact of a human cytomegalovirus subviral particle vaccine on the host cell proteome and on virus replication". Johannes Gutenberg-Universität Mainz, Dr. rer. nat. dissertation, pp. 15, 17, 34 (2021).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice).

Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at [SigmaAldrich.com/terms](https://www.sigmaaldrich.com/terms).

Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices).

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
A6926dat Rev 07/22 RBG,GCY,MAM

MERCK